Interview: Madhusudhan Venkatachari – CEO, Natco Pharma Canada
Madhu Venkat, CEO of Natco Pharma Canada, highlights the company’s portfolio strategy, its strategic road map to be the first mover and become a leading generic supplier in oncology by…
Natco Pharma (Canada) Inc. is a Canadian subsidiary of Natco Pharma Limited, India. Natco Pharma Limited is a vertically integrated pharmaceutical company heavily focused in R&D and in manufacturing drug intermediates, API and finished formulations. It has a global network and customer centric approach.
The company exports API’s and Formulations to around 50 countries across the globe. Well known for its impressive portfolio of Oncology, Neurology and CNS drugs, it is bringing to market niche pharmaceuticals.
Natco Pharma has been supplying high quality pharmaceuticals to the Canadian market for more than five years, and, since its formation, has set up a very professional Quality, Regulatory, Warehousing, Marketing, Distribution and Logistics capability to service the Canadian market.
The company is slated to launch some of its already approved generic products and in the process of getting approvals for some very niche and very significant pipeline of pharmaceuticals.
Contact:
Address: 2550 Argentina Road, Suite 116, Mississauga, ON, L5N 5R1 Canada
Tel.: +1 (905) 997 3353
Website: http://natcopharma.ca/
Madhu Venkat, CEO of Natco Pharma Canada, highlights the company’s portfolio strategy, its strategic road map to be the first mover and become a leading generic supplier in oncology by…
Drs Neil Cashman and Larry Altstiel of ProMIS Neurosciences weigh in on recent progress towards an effective therapy for Alzheimer’s disease, potentially representing a break from three decades of scientific…
Some of the top stories coming out of Canadian healthcare and life sciences, including a new GSK flu vaccine deal, Amylyx Pharmaceuticals’ first approval for an ALS drug, and the…
In April, the Canadian Ministry of Health announced the government would not be proceeding with certain proposed amendments to the Patented Medicines Regulations which govern the Patented Medicine Prices Review…
In conversation in the October edition of DIA’s Global Forum magazine, Canadian Agency for Drugs and Technologies in Health (CADTH) CEO Suzanne McGurn highlights how the work of HTA bodies…
Writing in the September edition of DIA’s Global Forum magazine, Dr Judith Glennie examines the specific steps that have been taken in the journey towards a National Pharmacare program in…
Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health Canada’s consultation with Canadians on what a national strategy for high-cost rare disease…
Clint Sharples, CEO of Heritage Cannabis, gives a potted history of the medical cannabis industry in Canada, its current legal status, provincial variations in patient registrations, financial performance, the impact…
As the only country in the world to boast a universal healthcare system that does not cover prescription drugs, Canada has been struggling with the concept of ‘national pharmacare’ for…
The latest news from Canadian pharma including deals for J&J’s and Novavax’s COVID-19 vaccines, an abrupt end to Canada’s participation in CanSino Biologics’ clinical trials the country’s first medical cannabis…
Pushback from drug companies on Canada’s newest drug pricing regulations has led the country’s regulatory body to reconsider their implementation. Companies cite the push for cost-effectiveness as a reason for…
Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for Alzheimer’s Disease (AD) treatments, and how Canada is playing a leading…
John L. Wallace of Antibe Therapeutics highlights how Canadian innovation stands to put the country at the forefront of the next wave of global biopharmaceutical R&D. BlueRock Therapeutics, a promising…
See our Cookie Privacy Policy Here
